Literature DB >> 15303570

Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density.

C A Pineau1, M B Urowitz, P J Fortin, D Ibanez, D D Gladman.   

Abstract

The purpose of this study was to evaluate the clinical characteristics of women with systemic lupus erythematosus (SLE) sent for a dual energy X-ray absorptiometry (DEXA) study, and to analyse the factors associated with a lower bone mineral density in these patients. Women with SLE who had a DEXA done between 1 January 1995 and 31 December 2000 were compared with those who did not have DEXA scans performed. SLE patients with osteoporosis (OP) were compared with those with a normal bone density. Of 516 women with SLE, 205 had a DEXA done. These patients had more traditional risk factors for osteoporosis, higher lupus disease activity, renal involvement, increased damage, higher mean steroid dose, increased use of immunosuppressants and occurrence of avascular necrosis. Of the 205 patients with DEXA, 18% had osteoporosis, 48.8% had osteopenia and 33.2% had normal bone mineral density. The two statistically significant predictors of a low bone density were a higher age at time of DEXA (P = 0.0003) and a higher SDI score (P = 0.0019). Osteoporosis is a significant comorbidity in SLE. Lupus patients referred for a DEXA have more traditional risk factors and use more corticosteroids. The main factors associated with a low bone density were however found to be age and increased damage. Interestingly, disease activity and corticosteroid use were not associated with osteoporosis in this study which may suggest other potential causes such as decreased physical activity associated with damage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15303570     DOI: 10.1191/0961203303lu1036oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  24 in total

Review 1.  [Glucocorticoid therapy in collagen diseases diseases].

Authors:  L Unger; M Kayser; M Enderlein; K Manger; H Nüsslein
Journal:  Z Rheumatol       Date:  2005-04       Impact factor: 1.372

Review 2.  Bone health and systemic lupus erythematosus.

Authors:  Chin Lee; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

3.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

Review 4.  Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.

Authors:  X Wang; S Yan; C Liu; Y Xu; L Wan; Y Wang; W Gao; S Meng; Y Liu; R Liu; D Xu
Journal:  Osteoporos Int       Date:  2016-01-11       Impact factor: 4.507

5.  Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis.

Authors:  Kui Zhang; Yan Zheng; Junfeng Jia; Jin Ding; Zhenbiao Wu
Journal:  Clin Rheumatol       Date:  2017-09-25       Impact factor: 2.980

6.  Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Hilda Sandoval-Cruz; Ricardo O Escárcega; Mario Jiménez-Hernández; Ivet Etchegaray-Morales; Elena Soto-Vega; Margarita Muñoz-Guarneros; Aurelio López-Colombo; Margarita Delezé-Hinojosa; Ricard Cervera
Journal:  Clin Rheumatol       Date:  2008-08-01       Impact factor: 2.980

7.  Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.

Authors:  Jennifer M P Woo; Zhuofeng Lin; Mohamad Navab; Casey Van Dyck; Yvette Trejo-Lopez; Krystal M T Woo; Hongyun Li; Lawrence W Castellani; Xuping Wang; Noriko Iikuni; Ornella J Rullo; Hui Wu; Antonio La Cava; Alan M Fogelman; Aldons J Lusis; Betty P Tsao
Journal:  Arthritis Res Ther       Date:  2010-05-18       Impact factor: 5.156

Review 8.  Glucocorticoid-induced osteoporosis in rheumatic diseases.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ernesto Canalis
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

Review 9.  Chronic pediatric inflammatory diseases: effects on bone.

Authors:  Anuradha Viswanathan; Francisco A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2007-12-29       Impact factor: 6.514

Review 10.  [Modern therapy for systemic lupus erythematosus].

Authors:  R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.